Royalty Report: Medical, Technical Know How, Drugs – Collection: 6137

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Technical Know How
  • Drugs
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6137

License Grant
The Licensee entered into an agreement in which the Licensor granted an exclusive and worldwide rights to certain patents and to certain other technical information. These rights remaim over the life of the patents and include, subject to limitations, the right to sublicense the patents.
License Property
Patents are related to protecting bioartificial liver technology and accompanying cell procurement/cryopreservation technologies.

Patent #5,888,409 – “Methods for Cell Isolation and Collection”
Patent #5,968,356 – “System for Hepatocyte Cell Isolation and Collection” and related European Patent #0 830 099 'Apararatus and Method for Cell Isolation and Collection'
Patent #6,140,123 – “Method for Conditioning and Cryopreserving Cells”

IPSCIO Record ID: 26667

License Grant
We acquired the Exclusive worldwide rights to US Patent # 6129911, for Liver Stem Cells from Licensor, a non-profit  hospital.  The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.
License Property
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.  This patent contains twenty-four claims to a method of obtaining a population of liver cell clusters from adult stem cells and is an important enhancement to the Company's adult stem cell portfolio.  (The Company has an exclusive, long-term license agreement for use of the following patents owned by the hospital related to liver cell lines and Liver Assist Devices (LADs)  US Patent #6,017,760, Isolation and Culture of Porcine Hepatocytes, expires October 9, 2015;  US Patent #6,107,043, Immortalized Hepatocytes, expires February 8, 2019;  US Patent #5,043,260, Perfusion Device for Hepatocytes, expires August 27, 2008;  US Patent #4,795,459, Implantable Prosthetic Device (Endothelial), expires January 3, 2006;  US Patent #6,129,911, Liver Stem Cell, expires October 10, 2017;  US Patent #6,858,146, Artificial Liver Apparatus and Method (Sybiol), expires on February 20, 2019; and  US Patent #6,872,389, Liver Stem Cell, expires on July 8, 2019.)

IPSCIO Record ID: 6686

License Grant
In April 2004, the Licensee acquired from Circe Biomedical a portfolio of intellectual properties, including certain U.S. and foreign patents applicable to the HepatAssist bioartificial liver that Circe Biomedical was developing, and including various patents related to the harvesting and handling of cells to be used in the bioartificial liver. We also assumed Circe Biomedical’s obligations to make the following royalty payments

We assumed the obligation to pay a royalty on any product that utilizes or incorporates the bioartificial liver patents, technology, inventions, and technical or scientific data that Circe Biomedical acquired from the Licensor, pursuant to that certain royalty Agreement, dated as of January 29, 1999, between Circe Biomedical (as a wholly-owned subsidiary of the Licensor) and Circe Acquisition Corp. The obligation to pay royalties on the net sales of certain parts of our bioartificial liver systems will continue for at least ten years after the date on which we have obtained all required regulatory approvals and have received $100,000 of net sales.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.